Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07609810
NA

Palmitoylethanolamide in Ulcerative Colitis

Sponsor: Ain Shams University

View on ClinicalTrials.gov

Summary

Evaluate the effects of PEA supplementation on disease activity, health-related quality of life (HRQoL) and inflammatory biomarkers in patients with active mild-to-moderate UC.

Official title: The Effect of Palmitoylethanolamide on the Clinical Outcomes in Ulcerative Colitis Patients

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-07-15

Completion Date

2029-02-15

Last Updated

2026-05-28

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Palmitoylethanolamide (PEA)

Palmitoylethanolamide (PEA) is an endocannabinoid-like bioactive lipid mediator which belongs to the family of N-acylethanolamine (NAE) fatty acid amides. It exerts anti-inflammatory, antioxidant, antimicrobial, analgesic, immunomodulatory and neuroprotective actions through acting at different sites like: PPAR-α, G-protein coupled receptor 55 (GPR55), cannabinoid receptors 1 and 2 (CB1 and CB2) and transient receptor potential vanilloid receptor 1 (TRPVR1) channels. PEA is a commercially available supplement mainly used to alleviate chronic neuropathic pain and persistent musculoskeletal pain. PEA has proven to be safe and tolerable across multiple studies with very rare cases reporting mild side effects like: intermittent headache, nausea, constipation, urticaria and fatigue. It will be given in this study at a dose of 600 mg/day

Locations (1)

Internal Medicine and Gastroenterology clinic, El-Demerdash Hospital

Cairo, El-Abbasia, Egypt